What is Phreesia?
Patient intake and healthcare-services workflow software company with $480.6M fiscal 2026 revenue scale.
- Category
- Patient intake and healthcare-services workflow software
- Headquarters
- Wilmington, DE
- Founded
- 2005
- Employees
- 2,000+
- Total funding
- Public company; not venture-round led
- Status
- NYSE: PHR
What is Phreesia?
Phreesia is a Patient intake and healthcare-services workflow software company headquartered in Wilmington, DE. As of June 2026, its clearest scale signal is $480.6M fiscal 2026 revenue.
Phreesia operates a patient-intake, access, payments, engagement, and life-sciences network serving healthcare services clients. Its core customer set includes medical groups, health systems, specialty practices, life-sciences brands, patients, and revenue-cycle teams, and its public product surface includes Patient intake, Scheduling, Registration, Payments, Insurance verification. The current scale signal is $480.6M fiscal 2026 revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Phreesia offer?
Phreesia offers Patient intake, Scheduling, Registration, Payments and related healthcare workflows.
- Patient intake· Core product
- Scheduling· Core product
- Registration· Core product
- Payments· Workflow
- Insurance verification· Workflow
- Patient activation· Workflow
- Life sciences media· Platform
- AccessOne patient financing· Platform
How does Phreesia make money?
Phreesia earns subscription, payment, implementation, and life-sciences media revenue from healthcare services clients and brand campaigns that run across patient workflows.
Phreesia earns subscription, payment, implementation, and life-sciences media revenue from healthcare services clients and brand campaigns that run across patient workflows. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Pricing is contracted by client size, provider count, modules, implementation scope, payments volume, and media campaign scale; the company reports revenue per average healthcare services client instead of public tiers. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Phreesia?
Phreesia is led by Chaim Indig, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Chaim IndigCo-founder and Chief Executive OfficerCEO since foundingLeads the patient-intake platform and public-company strategy.
- Evan RobertsCo-founder and Chief Operating OfficerCo-founderLeads operations and platform execution.
- Balaji GandhiChief Financial OfficerCFOOwns finance, capital allocation, and investor communications.
- Kristin RobertsChief Commercial OfficerCommercial leaderDrives go-to-market across provider and life-sciences customers.
How do you contact Phreesia's leadership?
Phreesia publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@phreesia.com (official published/company IR contact); personal executive format not verifiedHow much funding has Phreesia raised?
Phreesia is a public company (NYSE: PHR), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2005: Founded - Phreesia begins as a patient check-in and intake company. 2019: IPO - Phreesia lists publicly on the NYSE. 2023: Profitability push - Management emphasizes operating leverage and free-cash-flow improvement. 2025: AccessOne acquisition - Phreesia expands patient financing and access workflows. 2026: Fiscal 2026 results - Phreesia reports $480.6M in fiscal 2026 revenue and positive net income.
As of June 2026, Phreesia's practical funding capacity is best read through NYSE: PHR, $480.6M fiscal 2026 revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Phreesia access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Phreesia get here?
Phreesia grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2005Company foundedPhreesia starts in patient self-service intake.
- 2019Public listingPhreesia lists on the NYSE under PHR.
- 2021Life-sciences media scalesPatient activation becomes a larger network opportunity.
- 2024Operating leverageThe company narrows losses while expanding customers.
- 2025AccessOne closesPhreesia adds patient financing capabilities.
- 2026FY26 profitabilityPhreesia reports fiscal-year net income and $101.5M adjusted EBITDA.
Who are Phreesia's competitors?
Phreesia competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- athenahealthLarger ambulatory EHR, revenue-cycle, patient-engagement, and network-services platform.
- Experian HealthEligibility, patient access, identity, collections, and revenue-cycle products inside a broader data company.
- WaystarRevenue-cycle network and payments platform focused on claims, denials, and patient financial workflows.
- R1Outsourced revenue-cycle operations and technology for health systems and physician groups.
- NextGen HealthcareAmbulatory EHR, practice-management, analytics, and patient-experience competitor.
- TebraPractice-growth, billing, EHR, and patient-experience software for independent practices.
Phreesia — frequently asked questions
